Teva to Present at the Barclays Global Healthcare Conference
07 März 2023 - 10:00PM
Business Wire
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today
announced that Eli Kalif, EVP and Chief Financial Officer will
present at the Barclays Global Healthcare Conference on Tuesday,
March 14, 2023. The presentation will begin at 10:15 A.M. Eastern
Time.
To access a live webcast of the presentation, visit Teva’s
Investor Relations website at
https://ir.tevapharm.com/Events-and-Presentations.
An archived version of the webcast will be available within 24
hours after the end of the live discussion and will be accessible
for up to 90 days.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has
been developing and producing medicines to improve people’s lives
for more than a century. We are a global leader in generic and
innovative medicines with a portfolio consisting of over 3,500
products in nearly every therapeutic area. Around 200 million
people around the world take a Teva medicine every day, and are
served by one of the largest and most complex supply chains in the
pharmaceutical industry. Along with our established presence in
generics, we have significant innovative medicines research and
operations supporting our growing portfolio of innovative medicines
and biopharmaceutical products. Learn more at
www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This document and the conference call may contain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, which are based on
management’s current beliefs and expectations and are subject to
substantial risks and uncertainties, both known and unknown, that
could cause our future results, performance or achievements to
differ significantly from that expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to: our
ability to successfully compete in the marketplace; our substantial
indebtedness; our business and operations in general including: the
impact of global economic conditions and other macroeconomic
developments and the governmental and societal responses thereto;
compliance, regulatory and litigation matters; other financial and
economic risks; and other factors discussed in our Annual Report on
Form 10-K for the year ended December 31, 2022, including in the
sections captioned “Risk Factors.” Forward-looking statements speak
only as of the date on which they are made, and we assume no
obligation to update or revise any forward-looking statements or
other information contained herein, whether as a result of new
information, future events or otherwise. You are cautioned not to
put undue reliance on these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230307005198/en/
IR Contacts Ran Meir +1 (267) 468-4475 Sanjeev Sharma +1
(973) 658 2700 Yael Ashman +972 (3) 914 8262
PR Contacts Kelley Dougherty +1 (973) 832-2810 Eden Klein
+972 (3) 906 2645
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
Von Apr 2023 bis Apr 2024